ERBB2 and breast carcinoma: The ongoing MARGOT phase 2 randomized open‐label trial (NCT04425018) will compare neoadjuvant margetuximab to trastuzumab (both with pertuzumab plus paclitaxel) in patients with stage II–III HER2‐positive breast cancer who are low‐affinity CD16A‐158F carriers.